JPWO2020252129A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020252129A5 JPWO2020252129A5 JP2021573404A JP2021573404A JPWO2020252129A5 JP WO2020252129 A5 JPWO2020252129 A5 JP WO2020252129A5 JP 2021573404 A JP2021573404 A JP 2021573404A JP 2021573404 A JP2021573404 A JP 2021573404A JP WO2020252129 A5 JPWO2020252129 A5 JP WO2020252129A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- medicament according
- miglastat
- administered
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025076158A JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962859904P | 2019-06-11 | 2019-06-11 | |
| US62/859,904 | 2019-06-11 | ||
| PCT/US2020/037174 WO2020252129A1 (en) | 2019-06-11 | 2020-06-11 | Methods of treating fabry disease in patients having renal impairment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076158A Division JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536687A JP2022536687A (ja) | 2022-08-18 |
| JPWO2020252129A5 true JPWO2020252129A5 (enExample) | 2023-06-20 |
| JP7677910B2 JP7677910B2 (ja) | 2025-05-15 |
Family
ID=71950725
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573404A Active JP7677910B2 (ja) | 2019-06-11 | 2020-06-11 | 腎機能障害を有する患者のファブリー病を治療する方法 |
| JP2025076158A Pending JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025076158A Pending JP2025131572A (ja) | 2019-06-11 | 2025-05-01 | 腎機能障害を有する患者のファブリー病を治療する方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220313670A1 (enExample) |
| EP (1) | EP3982962A1 (enExample) |
| JP (2) | JP7677910B2 (enExample) |
| KR (1) | KR20220019796A (enExample) |
| CN (1) | CN114423427A (enExample) |
| AR (1) | AR120055A1 (enExample) |
| AU (1) | AU2020291002A1 (enExample) |
| BR (1) | BR112021024886A2 (enExample) |
| CA (1) | CA3141226A1 (enExample) |
| CL (1) | CL2021003280A1 (enExample) |
| EA (1) | EA202290024A1 (enExample) |
| IL (1) | IL288677A (enExample) |
| MX (1) | MX2021015352A (enExample) |
| PH (1) | PH12021553102A1 (enExample) |
| TW (1) | TW202112372A (enExample) |
| WO (1) | WO2020252129A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2533050T6 (pl) | 2006-05-16 | 2016-05-31 | Amicus Therapeutics Inc | Możliwości leczenia choroby Fabry'ego |
| DK3470077T3 (da) | 2008-02-12 | 2020-11-30 | Amicus Therapeutics Inc | Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner |
| CA3224546A1 (en) | 2017-05-30 | 2018-12-06 | Jeff Castelli | Use of migalastat in the treatment of fabry patients having renal impairment |
| JP7555818B2 (ja) | 2018-02-06 | 2024-09-25 | アミカス セラピューティックス インコーポレイテッド | 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用 |
| KR20220044560A (ko) | 2019-08-07 | 2022-04-08 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| AU2008232614A1 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of Fabry disease using pharmacological chaperones |
| US9056101B2 (en) * | 2007-04-26 | 2015-06-16 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| DK3470077T3 (da) | 2008-02-12 | 2020-11-30 | Amicus Therapeutics Inc | Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner |
| SG193379A1 (en) * | 2011-03-11 | 2013-10-30 | Amicus Therapeutics Inc | Dosing regimens for the treatment of fabry disease |
| IL313907A (en) * | 2016-07-19 | 2024-08-01 | Amicus Therapeutics Inc | Treatment of Fabry disease in patients experienced with ERT-NAIVE and ERT |
| MX2019008076A (es) * | 2017-01-05 | 2019-08-29 | Protalix Ltd | Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. |
| CA3224546A1 (en) * | 2017-05-30 | 2018-12-06 | Jeff Castelli | Use of migalastat in the treatment of fabry patients having renal impairment |
| AR111971A1 (es) * | 2017-05-30 | 2019-09-04 | Amicus Therapeutics Inc | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal |
| HUE069837T2 (hu) * | 2017-05-30 | 2025-04-28 | Amicus Therapeutics Inc | Bizonyos mutációkat hordozó Fabry-kóros betegek kezelése |
-
2020
- 2020-06-11 CA CA3141226A patent/CA3141226A1/en active Pending
- 2020-06-11 JP JP2021573404A patent/JP7677910B2/ja active Active
- 2020-06-11 CN CN202080042938.3A patent/CN114423427A/zh active Pending
- 2020-06-11 WO PCT/US2020/037174 patent/WO2020252129A1/en not_active Ceased
- 2020-06-11 AR ARP200101648A patent/AR120055A1/es unknown
- 2020-06-11 BR BR112021024886A patent/BR112021024886A2/pt unknown
- 2020-06-11 MX MX2021015352A patent/MX2021015352A/es unknown
- 2020-06-11 EP EP20751716.0A patent/EP3982962A1/en active Pending
- 2020-06-11 EA EA202290024A patent/EA202290024A1/ru unknown
- 2020-06-11 US US17/618,277 patent/US20220313670A1/en active Pending
- 2020-06-11 AU AU2020291002A patent/AU2020291002A1/en active Pending
- 2020-06-11 TW TW109119640A patent/TW202112372A/zh unknown
- 2020-06-11 KR KR1020227000878A patent/KR20220019796A/ko active Pending
- 2020-06-11 PH PH1/2021/553102A patent/PH12021553102A1/en unknown
-
2021
- 2021-12-05 IL IL288677A patent/IL288677A/en unknown
- 2021-12-09 CL CL2021003280A patent/CL2021003280A1/es unknown
-
2025
- 2025-05-01 JP JP2025076158A patent/JP2025131572A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020196750A (ja) | 線維症を処置するためのセニクリビロック併用療法 | |
| EP1741446B1 (en) | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | |
| KR101868991B1 (ko) | 피라졸 유도체 및 그 의약용도 | |
| US11033532B2 (en) | Uses of benzimidazole derivative for nocturnal acid breakthrough | |
| RU2070042C1 (ru) | Средство для лечения слабоумия, обусловленного цереброваскулярной патологией и болезнью альцгеймера | |
| BR112014023795B1 (pt) | Uso de inibidores de ccr3 | |
| PT2043637E (pt) | Métodos e medicamentos para administração de ibuprofeno | |
| JPH10510241A (ja) | Ｉｉ型糖尿病治療薬剤としてのケトコナゾール、および、その関連物質の使用法 | |
| JP2015537009A (ja) | 痛風の治療におけるブシラミンの使用 | |
| TW200843741A (en) | Pharmaceutical composition | |
| JPWO2020252129A5 (enExample) | ||
| JPWO2015129750A1 (ja) | 慢性腎臓病の進行抑制又は改善剤 | |
| US12090125B2 (en) | Combination therapy | |
| JPWO2004002473A1 (ja) | 血糖コントロール用医薬組成物 | |
| CN115397431A (zh) | 用于治疗涉及全身过度炎症反应的病症的eclitasertib | |
| BRPI0906158B1 (pt) | composição farmacêutica de liberação modificada compreendendo doxofilina e processo para a preparação de composição | |
| WO2024041633A1 (zh) | 一种稠环嘧啶类化合物的用途 | |
| CN115715191B (zh) | 排尿症状治疗剂 | |
| CN105663152A (zh) | 三乙酰基-3-羟基苯基腺苷在制备改善胰岛素抵抗及相关疾病中的应用 | |
| CN110831590A (zh) | 含有培马贝特的医药 | |
| JP4384435B2 (ja) | くしゃみ抑制組成物 | |
| CA2753754C (en) | Methods for treating schizophrenia | |
| JP5162161B2 (ja) | 炎症性疾患の予防または治療剤 | |
| JPH05504130A (ja) | 腫瘍壊死因子拮抗剤 | |
| JP7736327B2 (ja) | 高脂血症治療薬の調製におけるラパマイシンと併用するナリンギンの使用 |